×

Innovus Pharma Expands US Distribution by Signing a Non-Exclusive Sampling and Distribution Agreement With Bulu Box(R) for Zestra(R) in the US

SAN DIEGO, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma") www.innovuspharma.com (OTCQB:INNV), announced today it has entered into an non-exclusive sampling, marketing and distribution agreement with Bulu Box® ("Bulu Box") under which Bulu Box will add Zestra® as part of its monthly box to all current subscribers. In addition, Bulu Box will sell Zestra® 3 packettes box through its E-commerce platform in the US.

"Membership boxes are becoming very popular in the US and reach hundreds of thousands of members every month. This is a great way for Innovus to expand its sales channels in the US and make the product available to a large number of specific and targeted customers. We look forward to a great partnership with Bulu Box on our Zestra® product," said Dr. Bassam Damaj, Ph.D. President & CEO of Innovus Pharma.

"The benefit of a sampling and distribution partnership between Innovus and Bulu Box is in expanding the variety of health and wellness products we are able to offer our customers and subscribers," said Mr. Paul Jarret, Co-Founder and CEO of Bulu Box.

About Zestra® and FSI/AD

Zestra® is a patented blend of natural oils clinically-proven in double-blind placebo-controlled clinical trials in 276 women to increase in a statistical significant manner the arousal, desire and sexual satisfaction in Female Sexual Interest/Arousal Disorder (FSI/AD) women. Zestra® is the first NHP product to receive approval by Health Canada for the indication of Female Sexual Desire Disorder (FSDD) and the Company has filed for label expansion to FSI/AD in Canada. To date, no product has been approved in the Canada to treat FSI/AD, a persistent or recurring inability to attain or maintain adequate sexual excitement until the completion of a sexual activity. The diagnosis can also refer to an inadequate lubrication-swelling response normally present during arousal and sexual activity causing personal distress. Published papers on the FSI/AD market size estimate it to be equal or larger than the market for erectile dysfunction in males, and possibly larger.

About Bulu Box.

Bulu Box is a premium vitamin and supplement sample subscription company based in Lincoln, Nebraska, and founded in 2012. Brand partners such as Smarty Pants Vitamins, Linnet Pharmaceuticals and Shapeology Nutrition have collaborated with Bulu Box to connect with customers and get the most attention for their products. See Bulu Box in action with our "How It Works" video by visiting http://www.bulubox.com/pages/how-it-works.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging leader in the OTC male and female sexual dysfunction products. The Company generates revenues from its lead products Zestra® for female arousal, desire and satisfaction, and EjectDelay™ for premature ejaculation, and has a total of four marketed products in this space including Sensum+™ (for sales outside the U.S. only) and Zestra Glide®, a high viscosity low molarity water based lubricant.

For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com

Innovus Pharma's Forward-Looking Safe Harbor Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, to receive approval or meet the requirements of any relevant regulatory authority, to successfully commercialize such products and to achieve its other development, commercialization and financial goals, whether Bulu Box® will be able to successfully market and sell our products to its members. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

CONTACT: Innovus Pharma Contact: Kevin Holmes Chesapeake Group info@chesapeakegp.com T: 410-825-3930Source:Innovus Pharmaceuticals, Inc.